{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:54:44Z","timestamp":1794275684549,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":3648,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2006]]},"DOI":"10.1111\/j.1469-0691.2006.01342.x","type":"journal-article","created":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T04:25:48Z","timestamp":1138076748000},"page":"24-32","source":"Crossref","is-referenced-by-count":84,"special_numbering":"S1","title":["The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria"],"prefix":"10.1016","volume":"12","author":[{"given":"M.J.","family":"Rybak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1111\/j.1469-0691.2006.01342.x_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-0691.2005.01139.x","article-title":"Efficacy of current agents used in the treatment of Gram\u2010positive infections and the consequences of resistance","volume":"11","author":"Segreti","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2006.01342.x_bib2","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib3","author":"European Antimicrobial Resistance Surveillance System"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1086\/502221","article-title":"An outbreak of community\u2010onset methicillin\u2010resistant Staphylococcus aureus skin infections in southwestern Alaska","volume":"24","author":"Baggett","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/jama.286.10.1201","article-title":"Community\u2010acquired methicillin\u2010resistant Staphylococcus aureus in a rural American Indian community","volume":"286","author":"Groom","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib6","first-page":"88","article-title":"Outbreaks of community\u2010associated methicillin\u2010resistant Staphylococcus aureus skin infections\u2014Los Angeles County, California, 2002\u20132003","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib7","first-page":"793","article-title":"Methicillin\u2010resistant Staphylococcus aureus infections among competitive sports participants\u2014Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000\u20132003","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa043252","article-title":"Methicillin\u2010resistant Staphylococcus aureus disease in three communities","volume":"352","author":"Fridkin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib9","first-page":"322","article-title":"Brief report: vancomycin\u2010resistant Staphylococcus aureus\u2014New York, 2004","volume":"53","author":"Kacica","year":"2004","journal-title":"MMWR"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin\u2010resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib11","author":"Rudrick"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.48.1.275-280.2004","article-title":"Vancomycin\u2010resistant Staphylococcus aureus isolate from a patient in Pennsylvania","volume":"48","author":"Tenover","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jac\/dkf246","article-title":"Linezolid\u2010resistant enterococci: report of the first isolates in the United Kingdom","volume":"50","author":"Auckland","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of Staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003495-200262030-00002","article-title":"Treatment options for vancomycin\u2010resistant enterococcal infections","volume":"62","author":"Linden","year":"2002","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1592\/phco.24.1.41.34802","article-title":"Daptomycin","volume":"24","author":"Tedesco","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib18","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1021\/bi00413a009","article-title":"Fluorescence indicates a calcium\u2010dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes","volume":"27","author":"Lakey","year":"1988","journal-title":"Biochemistry"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib19","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib21","series-title":"Physicians' Desk Reference","author":"Anonymous","year":"2005"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.13.9.1159","article-title":"Lipopeptides, focusing on daptomycin, for the treatment of Gram\u2010positive infections","volume":"13","author":"Eisenstein","year":"2004","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cbi.2004.08.004","article-title":"An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes","volume":"150","author":"Oleson","year":"2004","journal-title":"Chem Biol Interact"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin\u2013dalfopristin against staphylococci and enterococci, including vancomycin\u2010intermediate and \u2010resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2004.06.014","article-title":"Clinical glycopeptide\u2010intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline","volume":"50","author":"LaPlante","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib27","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1128\/AAC.47.12.3960-3963.2003","article-title":"Bactericidal activities of daptomycin, quinupristin\u2013dalfopristin, and linezolid against vancomycin\u2010resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib28","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib29","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/AAC.44.7.1925-1929.2000","article-title":"In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and\/or in combination against glycopeptide intermediate\u2010resistant Staphylococcus aureus in an infection model","volume":"44","author":"Akins","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jac\/48.2.219","article-title":"The in vitro activity of daptomycin against 514 Gram\u2010positive aerobic clinical isolates","volume":"48","author":"King","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkg130","article-title":"Activity of daptomycin against susceptible and multidrug\u2010resistant Gram\u2010positive pathogens collected in the SECURE study (Europe) during 2000\u20132001","volume":"51","author":"Critchley","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0732-8893(00)00164-4","article-title":"Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests","volume":"38","author":"Fuchs","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2004.07.002","article-title":"Antimicrobial activity of daptomycin against multidrug\u2010resistant Gram\u2010positive strains collected worldwide","volume":"50","author":"Sader","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin\u2010resistant Staphylococcus aureus strain isolated at the Hershey Medical Center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jac\/49.3.467","article-title":"In vitro bactericidal activity of daptomycin against staphylococci","volume":"49","author":"Fuchs","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib36","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high\u2010inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/AAC.36.5.1109","article-title":"Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram\u2010positive endocarditis and bacteremia","volume":"36","author":"Rybak","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib38","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.44.12.3447-3450.2000","article-title":"Comparative in vitro activities of daptomycin and vancomycin against resistant gram\u2010positive pathogens","volume":"44","author":"Snydman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jac\/dkh104","article-title":"Daptomycin synergy with rifampicin and ampicillin against vancomycin\u2010resistant enterococci","volume":"53","author":"Rand","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000239141","article-title":"Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin\u2010susceptible and high\u2010level\u2010gentamicin\u2010resistant enterococci","volume":"39","author":"Louie","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib41","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1128\/AAC.33.8.1198","article-title":"In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin\u2010susceptible and methicillin\u2010resistant Staphylococcus aureus strains","volume":"33","author":"Bush","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib42","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/AAC.45.6.1799-1802.2001","article-title":"Resistance studies with daptomycin","volume":"45","author":"Silverman","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib43","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1128\/JCM.43.10.5285-5287.2005","article-title":"Development of daptomycin resistance in vivo in methicillin\u2010resistant Staphylococcus aureus","volume":"43","author":"Hayden","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib44","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1128\/JCM.43.10.5384-5387.2005","article-title":"Clinical progression of methicillin\u2010resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin","volume":"43","author":"Vikram","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib45","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/428616","article-title":"Daptomycin\u2010resistant, methicillin\u2010resistant Staphylococcus aureus bacteremia","volume":"40","author":"Mangili","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib46","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","article-title":"Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy","volume":"49","author":"Sabol","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1086\/432121","article-title":"Emergence of resistance to daptomycin during treatment of vancomycin\u2010resistant Enterococcus faecalis infection","volume":"41","author":"Munoz\u2010Price","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib48","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4065\/80.9.1215","article-title":"Daptomycin\u2010resistant Enterococcus faecium in a patient with acute myeloid leukemia","volume":"80","author":"Long","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib49","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nrd1258","article-title":"Daptomycin","volume":"2","author":"Raja","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin\u2010structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib51","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1517\/14656566.5.11.2321","article-title":"Daptomycin\u2014a novel antibiotic against Gram\u2010positive pathogens","volume":"5","author":"LaPlante","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib52","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01342.x_bib53","author":"Cubist Pharmaceuticals"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15600854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15600854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T22:16:54Z","timestamp":1555366614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15600854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":53,"alternative-id":["S1198743X15600854"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01342.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2006]]}}}